Supplementary information

Title:

Dextran-g-Lauric Acid as IKK Complex Inhibitor Carrier

Chao-Ming Su [a], Ching Lin [a], Chen-Yu Huang [b†], Jih-Chao Yeh [a], Tien-Yao Tsai [a], Tzong Rong Ger [a†], Ming-Chen Wang [a], Shyh-Liang Lou [a†]

[a.] Department of Biomedical Engineering, College of Engineering, Chung Yuan

Christian University, Chungli 32023, Taiwan, R.O.C.

[b.] Department of Physics and Astronomy, Johns Hopkins University, MD 21218, USA.

† Co-corresponding authors.

Fig. 1s. The CMC plots of DexLA.

Fig. 2s. 1H NMR spectrum of dextran-g-lauric acid in D_2O. (a) $Dex_6LA_{0.75}$, (b) $Dex_6LA_{1.5}$, (c) $Dex_{40}LA_{0.75}$, and (d) $Dex_{40}LA_{1.5}$.

Fig. 3s. UV-Vis spectrum of IMD-$Dex_6LA_{1.5}$, $Dex_6LA_{1.5}$ and IMD-0354.


Fig. 4s. The structure of DexLA.

Fig. 5s. ATP analysis of B16F10 cell cultured with IMD-Dex$_6$LA$_{1.5}$ or IMD-0354.

Table 1s. The drug loading of IMD-DexLA

Sample	Dex-LA:Drug (w/w)	EE (wt %)	DL (wt %)
Dex$_6$LA$_{1.5}$	20:1	93.75 %	4.67 %
Dex$_6$LA$_{1.5}$	10:1	91.58 %	9.15 %